这项工作旨在利用新型炎症生物标志物淋巴细胞与单核细胞比率 (LMR) 来研究 LMR 与前列腺癌 (PCa) 之间的潜在联系。对 2001 年至 2010 年参与全国健康和营养检查调查的 7706 名男性参与者进行了一项横断面研究调查。多元逻辑回归模型研究了 LMR 水平与 PCa 风险之间的关系。此外，还进行了阈值分析、亚组分析、交互作用检验和平滑曲线拟合。即使在控制了潜在的混杂因素后，LMR 与 PCa 风险之间仍存在显着负相关（OR = 0.79，95% CI：0.65-0.97，P = .0002）。通过平滑曲线拟合发现LMR和PCa之间存在显着的非线性负相关，具有阈值效应，断点为4.86。亚组分析显示，PCa 与 LMR 与高血压的负相关之间存在显着的交互作用（交互作用 P = 0.0448）。此外，额外的分层平滑曲线拟合表明 PCa 风险与 LMR 之间存在统计学上显着的负相关关系。根据我们的研究结果，PCa 风险与 LMR 水平之间存在显着的负相关关系。炎症反应相关指标快速、易于使用，并提供一定的临床参考。然而，需要更广泛的前瞻性调查来确认 LMR 水平与 PCa 的关系。版权所有 © 2024 作者。由 Wolters Kluwer Health, Inc. 出版

Using the novel inflammatory biomarker lymphocyte-to-monocyte ratio (LMR), this work aimed to look into any potential connections between LMR and prostate cancer (PCa). A cross-sectional research investigation was conducted on 7706 male participants involved in the National Health and Nutrition Examination Survey from 2001 to 2010. Multivariate logistic regression modeling investigated the relationship between LMR levels and PCa risk. Furthermore, threshold analysis, subgroup analysis, interaction testing, and smoothed curve fitting were carried out. A significant negative correlation was seen between LMR and PCa risk (OR = 0.79, 95% CI: 0.65-0.97, P = .0002), even after controlling for potential confounding factors. A significant nonlinear negative correlation with a threshold effect and a breakpoint of 4.86 was found by smooth curve fitting between LMR and PCa. Subgroup analysis revealed a significant interaction (P for interaction = 0.0448) between the negative correlation between PCa and LMR about hypertension. Moreover, additional stratified smoothed curve fitting demonstrated a statistically significant inverse relationship between PCa risk and LMR. According to our findings, there is a substantial inverse relationship between PCa risk and LMR level. The inflammatory response-related index is quick, easy to use, and offers some clinical references. However, more extensive prospective investigations are required to confirm the involvement of LMR levels in PCa.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.